Literature DB >> 23977447

Effect of epigenetic histone modifications on E-cadherin splicing and expression in lung cancer.

Wei Liao1, Gwen Jordaan, Minu K Srivastava, Steven Dubinett, Sherven Sharma, Sanjai Sharma.   

Abstract

We have identified an alternatively spliced, non-functional aberrant E-cadherin transcript that lacks exon 11 and is over expressed in malignant cells as compared to the normal non-malignant cells. This increase in the aberrant transcript is a mechanism of loss of E-cadherin gene expression as it is rapidly degraded by the nonsense mediated decay pathway. To study the mechanism of this gene missplicing we analyzed the role of histone epigenetic modifications in lung cancer cell lines. The treatment of low E-cadherin lung cancer cell lines with histone deacetylase inhibitor (HDACi, MS-275) resulted in the preferential expression of the correctly spliced transcripts in the low E-cadherin expressing cell lines only. Chromatin immunoprecipitation (ChIP) assays revealed that the histone hypoacetylation levels correlate with aberrant exon 11 splicing as there is more aberrant splicing in cell lines with E-cadherin promoter hypoacetylation. Inactivation of histone deacetylases (HDAC) 1, 2 and 3 resulted in an increase in E-cadherin expression and an increase in the ratio of the correctly spliced E-cadherin transcript. As transcription of the gene is closely linked to splicing, we considered the possibility that change in E-cadherin transcription correlates with splicing. The Zeb1 epithelial-mesenchymal transformation (EMT) inducer silences E-cadherin expression and could also alter the splicing of this exon. Inhibition of the E-cadherin promoter transcription with Zeb1 expression increases aberrant splicing and the reverse is observed when Zeb1 is knocked down. The role of HDAC inhibitors was also studied in vivo in a immunodeficient mouse xenograft model. Exposure of mice to HDACi resulted in growth inhibition, increase in E-cadherin expression, alteration of aberrant splicing and the reversal of EMT in mouse tumors. The findings support the modulation of E-cadherin exon 11 inclusion or exclusion by histone epigenetic modifications as they change the overall chromatin structure. The results provide an interesting link between epigenetic alterations in cancer cells and gene splicing in addition to their effect on gene silencing.

Entities:  

Keywords:  E-cadherin; EMT; HDAC; HDAC inhibitor; Zeb1; histone modifications; splicing

Year:  2013        PMID: 23977447      PMCID: PMC3744017     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  54 in total

1.  Knockdown of ZEB1, a master epithelial-to-mesenchymal transition (EMT) gene, suppresses anchorage-independent cell growth of lung cancer cells.

Authors:  Yoshihiro Takeyama; Mitsuo Sato; Mihoko Horio; Tetsunari Hase; Kenya Yoshida; Toshihiko Yokoyama; Harunori Nakashima; Naozumi Hashimoto; Yoshitaka Sekido; Adi F Gazdar; John D Minna; Masashi Kondo; Yoshinori Hasegawa
Journal:  Cancer Lett       Date:  2010-05-07       Impact factor: 8.679

Review 2.  The carboxy terminal domain of RNA polymerase II and alternative splicing.

Authors:  Manuel J Muñoz; Manuel de la Mata; Alberto R Kornblihtt
Journal:  Trends Biochem Sci       Date:  2010-04-24       Impact factor: 13.807

3.  The C-terminal domain of the largest subunit of RNA polymerase II interacts with a novel set of serine/arginine-rich proteins.

Authors:  A Yuryev; M Patturajan; Y Litingtung; R V Joshi; C Gentile; M Gebara; J L Corden
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

4.  Chromatin, transcript elongation and alternative splicing.

Authors:  Alberto R Kornblihtt
Journal:  Nat Struct Mol Biol       Date:  2006-01       Impact factor: 15.369

Review 5.  Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?

Authors:  Héctor Peinado; David Olmeda; Amparo Cano
Journal:  Nat Rev Cancer       Date:  2007-05-17       Impact factor: 60.716

6.  Aberrant splicing of the E-cadherin transcript is a novel mechanism of gene silencing in chronic lymphocytic leukemia cells.

Authors:  Sanjai Sharma; Alan Lichtenstein
Journal:  Blood       Date:  2009-09-10       Impact factor: 22.113

7.  Epigenetic features are significantly associated with alternative splicing.

Authors:  Yuanpeng Zhou; Yulan Lu; Weidong Tian
Journal:  BMC Genomics       Date:  2012-03-29       Impact factor: 3.969

8.  Global levels of histone modifications predict prognosis in different cancers.

Authors:  David B Seligson; Steve Horvath; Matthew A McBrian; Vei Mah; Hong Yu; Sheila Tze; Qun Wang; David Chia; Lee Goodglick; Siavash K Kurdistani
Journal:  Am J Pathol       Date:  2009-04-06       Impact factor: 4.307

Review 9.  Alternative and aberrant splicing of MDM2 mRNA in human cancer.

Authors:  Frank Bartel; Helge Taubert; Linda C Harris
Journal:  Cancer Cell       Date:  2002-07       Impact factor: 31.743

10.  Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma.

Authors:  Barbara A Frederick; Barbara A Helfrich; Christopher D Coldren; Di Zheng; Dan Chan; Paul A Bunn; David Raben
Journal:  Mol Cancer Ther       Date:  2007-05-31       Impact factor: 6.261

View more
  12 in total

Review 1.  The Kraken Wakes: induced EMT as a driver of tumour aggression and poor outcome.

Authors:  Andrew D Redfern; Lisa J Spalding; Erik W Thompson
Journal:  Clin Exp Metastasis       Date:  2018-06-08       Impact factor: 5.150

2.  Prediction of non-small cell lung cancer metastasis-associated microRNAs using bioinformatics.

Authors:  Rong Wang; Xiao-Feng Chen; Yong-Qian Shu
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

3.  Integrated Assessment of Viral Transcription, Antigen Presentation, and CD8+ T Cell Function Reveals Multiple Limitations of Class I-Selective Histone Deacetylase Inhibitors during HIV-1 Latency Reversal.

Authors:  Talia M Mota; Chase D McCann; Ali Danesh; Szu-Han Huang; Dean B Magat; Yanqin Ren; Louise Leyre; Tracy D Bui; Thomas M Rohwetter; Colin M Kovacs; Erika Benko; Lynsay MacLaren; Avery Wimpelberg; Christopher M Cannon; W David Hardy; Jeffrey T Safrit; R Brad Jones
Journal:  J Virol       Date:  2020-04-16       Impact factor: 5.103

Review 4.  HDACs and HDAC Inhibitors in Cancer Development and Therapy.

Authors:  Yixuan Li; Edward Seto
Journal:  Cold Spring Harb Perspect Med       Date:  2016-10-03       Impact factor: 6.915

Review 5.  A new role for the PI3K/Akt signaling pathway in the epithelial-mesenchymal transition.

Authors:  Wenting Xu; Zhen Yang; Nonghua Lu
Journal:  Cell Adh Migr       Date:  2015-08-04       Impact factor: 3.405

6.  An epithelial marker promoter induction screen identifies histone deacetylase inhibitors to restore epithelial differentiation and abolishes anchorage independence growth in cancers.

Authors:  H M Tang; K T Kuay; P F Koh; M Asad; T Z Tan; V Y Chung; S C Lee; J P Thiery; Ry-J Huang
Journal:  Cell Death Discov       Date:  2016-06-13

7.  Novel Polyamine-Naphthalene Diimide Conjugates Targeting Histone Deacetylases and DNA for Cancer Phenotype Reprogramming.

Authors:  Alice Pasini; Chiara Marchetti; Claudia Sissi; Marilisa Cortesi; Emanuele Giordano; Anna Minarini; Andrea Milelli
Journal:  ACS Med Chem Lett       Date:  2017-10-24       Impact factor: 4.345

8.  The strong propensity of Cadherin-23 for aggregation inhibits cell migration.

Authors:  Malay K Sannigrahi; Cheerneni S Srinivas; Nilesh Deokate; Sabyasachi Rakshit
Journal:  Mol Oncol       Date:  2019-03-19       Impact factor: 6.603

9.  Proteomic Analysis of Zeb1 Interactome in Breast Carcinoma Cells.

Authors:  Sergey E Parfenyev; Sergey V Shabelnikov; Danila Y Pozdnyakov; Olga O Gnedina; Leonid S Adonin; Nickolai A Barlev; Alexey G Mittenberg
Journal:  Molecules       Date:  2021-05-24       Impact factor: 4.411

Review 10.  Transcription regulation of E-cadherin by zinc finger E-box binding homeobox proteins in solid tumors.

Authors:  Thian-Sze Wong; Wei Gao; Jimmy Yu-Wai Chan
Journal:  Biomed Res Int       Date:  2014-08-13       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.